Journal of Surgical Research
Volume 95, Issue 2 , Pages 200-206 , February 2001

Clinical Applications of Magnetic Drug Targeting

  • Andreas S. Lübbe, M.D., Ph.D.

      Affiliations

    • Cecilien-Klinik, Lindenstrasse 26, 33175, Bad Lippspringe, Germany
    • ,
  • Christoph Alexiou

      Affiliations

    • Kinikum rechts der Isar, Ismaningerstrasse 22, 81675, München, Germany
    • ,
  • Christian Bergemann

      Affiliations

    • Bamberger Straße 51, 10777, Berlin, Germany

References 

    REFERENCES
  1. Hofmann MA, Pursa JJ, Swash DF. Annual variations in the vasopressin neuron population of the human suprachiasmatic nucleus. Neuroscience. 1993;53:1003
  2. Schilsky RL, Milano GA, Ratain MJ. Principles of Antineoplastic Drug Development and Pharmacology. New York: Dekker; 1996;
  3. Wielgus-Serafinska E, Plwka A, Ksminski M. Circadian variation of mitrochondrial succinic dehydrogenase and microsomal cytochrome P-450 dependent monooxygenase activity in the liver of sexually immature and mature rats. J. Physiol. Pharmacol. 1993;44:55
  4. Badwe RA, Gregory WM, Chaudary MA. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 1991;25:1261
  5. Senie R, Rosen P, Rhodes P. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann. Intern. Med. 1991;115:337
  6. Bruguerolle B. Circadian phase dependent pharmacokinetics of disopyramide. Chronobiol. Int. 1984;1:267
  7. Ratajczak HV, Sothern RB, Hrushesky WJM. Estrous influence on surgical cure of a mouse breast cancer. J. Exp. Med. 1988;168:88
  8. Meyer, K. Season and cycle: Variation in presentation and response to therapy in premenopausal breast cancer. In 77th Annual Clinical Congress, Oct. 21–24, Chicago, IL, 1991.
  9. Waterhouse JM, Minors DS. Temporal aspects of renal drug elimination. In:  Lemmer B editors. Chronopharmacology: Cellular and Biochemical Interactions. New York: Dekker; 1989;p. 35–50
  10. Smaaland R, Svardal AM, Lote K. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J. Natl. Cancer Inst. 1991;83:1092
  11. Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin. Pharmacokinet. 1982;7:401
  12. Conroy RTWL, Mills JN. Human Circadian Rhythms. London: Churchill; 1970;
  13. Portaluppi F, Vergnani L. Atrial natriuretic peptide and circadian blood pressure regulation: Clues from a chronobiologic approach. Chronobiology. 1993;10:176
  14. Hrushesky WJM, Levi F, Halberg F. Circadian stage dependence of cis-diammine-dichloroplatinum lethal toxicity in rats. Cancer Res. 1982;42:945
  15. Scheving LE, Tsai TS, Feuers RJ. Cellular mechanisms involved in the action of anticancer drugs. In:  Lemmer B editors. Chronopharmacology: Cellular and Biochemical Interactions. New York: Dekker; 1989;p. 317–369
  16. Killmann SA, Cronkite EP, Fliedner TM. Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitosis. Blood. 1962;19:743
  17. Laerum OD, Sletvold O, Riise T. Circadian and circannual variation of the cell cycle distribution in the mouse bone marrow. Chronobiol. Int. 1988;5:19
  18. Smaaland R, Lote K, Sothern R. DNA synthesis and ploidy in non-Hodkin's lymphomas demonstrate variation depending on the circadian stage of cell sampling. Cancer Res. 1993;53:3129
  19. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 1990;48:381
  20. Moore RY, Speh JC. GABA is the principal neurotransmitter of the circadian system. Neurosci. Lett. 1992;150:112
  21. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 1990;48:129
  22. el Kouni MH, Naguib FNM, Park KS. Circadian rythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol. 1990;40:2479
  23. von Roemeling R, Mormont MC, Walker K. Cancer control depends upon the circadian shape of continuous FUDR infusion. Proc. Am. Assoc. Cancer Res. 1987;28:A1293
  24. Sieben, S, Bergemann, C, Lübbe, A, Brockmann, B, and, Reischeleit, D. Comparison of different particles and methods for magnetic isolation of circulating tumor cells, J. Magn. Magn. Mater. (in press).
  25. Singh M, Ferdous AJ, Branham M. Trends in drug targeting for cancer treatment. Drug Delivery. 1996;3:289
  26. Seyei A, Widder K, Czerlinski G. Magnetic guidance of drug carrying microspheres. J. Appl. Phys. 1978;49:3578
  27. Jordan A, Wust P, Scholz R, Tesche B, Fähling H, Mitrovics T, et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int. Hypertherm. 1996;12:705
  28. Kato T, Nemoto R, Mori H, Unno K, Goto A, Homma M. An approach to magnetically controlled cancer chemotherapy. J. Jpn. Soc. Cancer Ther. 1980;15:876
  29. Inada Y, Ohwada K, Yoshimoto T, Kojima T, Takahashi K, Kodera Y, et al. Fibrinolysis by urokinase endowed with magnetic property. Biochem. Biophys. Res. Commun. 1987;148:392
  30. Viroonchaptan E, Ueno M, Sato H, Adachi I, Nagae H, Tazawa K, et al. Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: An on-line flow system for quantifying magnetic responsiveness. Pharmaceut. Res. 1995;12:1176
  31. Pulfer SK, Gallo JM. Targeting magnetic microsheres to brain tumors. In:  Häfeli U,  Schütt W,  Teller J,  Zborowski M editor. Scientific and Clinical Applications of Magnetic Carriers. New York: Plenum Press; 1997;p. 445–455
  32. Allen LM, Kent JW, Wolfe C, Ficco C, Johnson J. MTCMT: A magnetically targetable drug carrier for paclitaxel. In:  Häfeli U,  Schütt W,  Teller J,  Zborowski M editor. Scientific and Clinical Applications of Magnetic Carriers. New York: Plenum Press; 1997;p. 481–494
  33. Häfeli UO, Pauer GJ, Roberts WK, Humm JL, Macklis RM. Magnetically targeted microspheres for intracavitary and intraspinal 90Y radiotherapy. In:  Häfeli U,  Schütt W,  Teller J,  Zborowski M editor. Scientific and Clinical Applications of Magnetic Carriers. New York: Plenum Press; 1997;p. 501–516
  34. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J. Magn. Magn. Mater. 1999;194:132
  35. Fabry B, Maksym GN, Hubmayr RD, Butler JP, Fredberg JJ. Implications of heterogeneous bead behavior on cell mechanical properties measured with magnetic twisting cytometry. J. Magn. Magn. Mater. 1999;194:120
  36. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, et al. Drugs ten years later: Epirubicin. Ann. Oncol. 1993;4:359
  37. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56:4686
  38. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer Res. 1996;56:4694
  39. Lübbe AS, Bergemann C. Magnetically-controlled drug targeting. Cancer J. 1998;11:
  40. Lübbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drug-targeting. J. Magn. Magn. Mater. 1999;194:149
  41. Alexiou, C, Arnold, W, Klein, R, Parak, F. G, Hulin, P, Bergemann, C, Erhardt, W, Wagenpfeil, S, and, Lübbe, A. S. Locoregional cancer treatment with “Magnetic Drug Targeting.” Cancer Res, (in press).
  42. Bergemann C, Müller-Schulte D, Oster J, à Brassard , Lübbe AS. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications. J. Magn. Magn. Mater. 1999;194:45

PII: S0022-4804(00)96030-X

doi: 10.1006/jsre.2000.6030

Journal of Surgical Research
Volume 95, Issue 2 , Pages 200-206 , February 2001

Article Tools